Background
Methods
Patients' selection
Treatment
Immunohistochemistry
Statistical analysis
Results
Patients characteristics
Characteristics | N | % | |
---|---|---|---|
Total | 207 | 100 | |
Age (range) | 56 | (30-88) | |
Tumor size | |||
T1 | 121 | 58,50% | |
T2 | 76 | 36,70% | |
T3-T4 | 10 | 4,80% | |
Lymph node | |||
Negative | 106 | 51,20% | |
Positive | 101 | 48,80% | |
Histology | |||
Ductal | 173 | 83,60% | |
Lobular | 24 | 11,60% | |
Other | 10 | 4,80% | |
Tumor grade (Scarff-Bloom-Richardson) | |||
1 | 52 | 25,10% | |
2 | 96 | 46,40% | |
3 | 59 | 28,50% | |
Estrogen receptor | |||
Negative | 53 | 25,60% | |
Positive | 153 | 73,90% | |
Progesterone receptor | |||
Negative | 61 | 29,50% | |
Positive | 145 | 70,00% | |
Her2-neu expression (IHC) | |||
0, 1+ or 2+ | 182 | 87,90% | |
3+ | 22 | 10,60% | |
Unknown | 3 | 1,40% | |
CCR6 expression on Tumor cells | |||
Negative | 130 | 64,4% | |
Positive | 72 | 35,6% | |
CCR7 expression on Stromal cells | |||
Negative | 118 | 57,0% | |
Positive | 89 | 43,0% | |
CCL19 expression on Tumor cells | |||
Negative | 95 | 46,6% | |
Positive | 109 | 53,4% | |
CCL19 expression on Dendritic cells | |||
Negative | 103 | 50,5% | |
Positive | 101 | 49,5% |
Chemokines and chemokine receptors expression on tumor samples
Association of chemokines and chemokine receptors expression with clinicopathological variables
Association of chemokines and chemokine receptors expression with relapse-free and overall survival
Characteristics | N | Mean RFS (years) | 95% CI | p value for LR | Mean OS (years) | 95% CI | p value for LR |
---|---|---|---|---|---|---|---|
Age (range) | |||||||
< 40 years | 15 | 8.1 | 6.3-10.0 | 10.6 | 10.1-11.1 | ||
40-55 years | 82 | 11.1 | 10.5-11.7 | 11.2 | 10.7-11.8 | ||
> 55 years | 110 | 10.3 | 9.6-11.1 | 0.084 | 10.2 | 9.5-10.9 | 0.051 |
Tumor size | |||||||
T1 | 121 | 11.1 | 10.6-11.7 | 11.1 | 10.6-11.7 | ||
T2 | 76 | 10.0 | 9.1-10.8 | 10.5 | 9.9-11.2 | ||
T3-T4 | 10 | 6.1 | 2.9-9.4 |
< 0.001
| 6.6 | 3.6-9.6 |
< 0.001
|
Lymph node | |||||||
Negative | 106 | 11.0 | 10.5-11.7 | 11.2 | 10.7-11.7 | ||
Positive | 101 | 10.0 | 9.2-10.7 |
0.031
| 10.1 | 9.4-10.8 |
0.030
|
Histology | |||||||
Ductal | 173 | 10.6 | 10.0-11.1 | 10.6 | 10.1-11.1 | ||
Lobular | 24 | 10.5 | 9.1-11.9 | 11.5 | 10.8-12.3 | ||
Other | 10 | 9.8 | 7.4-12.3 | 0.722 | 10.4 | 7.8-12.9 | 0.410 |
Tumor grade (Scarff-Bloom-Richardson) | |||||||
I | 52 | 11.9 | 11.4-14.4 | 11.7 | 11.1-12.3 | ||
II | 96 | 10.4 | 9.6-11.1 | 10.6 | 10.0-11.2 | ||
III | 59 | 9.4 | 8.2-11.1 |
0.003
| 9.9 | 8.9-10.9 |
0.024
|
Estrogen receptor | |||||||
Negative | 53 | 9.6 | 8.4-10.7 | 10.2 | 9.2-11.2 | ||
Positive | 153 | 11.0 | 10.5-11.5 |
0.012
| 11.0 | 10.5-11.5 | 0.354 |
Progesterone receptor | |||||||
Negative | 61 | 9.5 | 8.4-10.6 | 9.9 | 9.0-10.9 | ||
Positive | 145 | 11.1 | 10.6-11.6 |
0.013
| 11.2 | 10.7-11.6 |
0.035
|
Her2-neu expression (IHC) | |||||||
0, 1+ or 2+ | 182 | 10.6 | 10.1-11.1 | 10.7 | 10.3-11.2 | ||
3+ | 22 | 9.7 | 8.4-10.9 | 0.819 | 10.1 | 9.2-11.0 | 0.886 |
CCR6 on tumor cells | |||||||
Negative | 130 | 11.0 | 10.4-11.6 | 10.9 | 10.3-11.4 | ||
Positive | 72 | 9.9 | 9.0-10.8 |
0.032
| 10.5 | 9.8-11.2 | 0.400 |
CCR7 on stromal cells | |||||||
Negative | 118 | 10.8 | 10.2-11.5 | 11.0 | 10.5-11.6 | ||
Positive | 89 | 10.3 | 9.4-11.1 | 0.344 | 10.4 | 9.6-11.1 | 0.153 |
CCL19 on tumor cells | |||||||
Negative | 95 | 10.4 | 9.6-11.2 | 10.7 | 10.0-11.3 | ||
Positive | 109 | 10.7 | 10.0-11.4 | 0.730 | 10.8 | 10.2-11.4 | 0.962 |
CCL19 on dendritic cells | |||||||
Negative | 103 | 11.0 | 10.4-11.7 | 11.0 | 10.3-11.5 | ||
Positive | 101 | 9.8 | 9.1-10.6 |
0.042
| 10.2 | 9.6-10.9 | 0.271 |
Relapse-free survival | |||
---|---|---|---|
Variable | Hazard Ratio | 95% CI | p value |
Tumor size (mm) | 1.031 | [1.005-1.056] |
0.018
|
Number of positive node | 1.086 | [1.030-1.155] |
0.002
|
SBR grade 2 (ref. SBR1) | 1.945 | [0.551-6.871] | 0.302 |
SBR grade 3 (ref. SBR1) | 2.349 | [0.628-8.794] | 0.205 |
Estrogen receptor (negative) | 1.527 | [0.658-3.543] | 0.325 |
Progesterone receptor (negative) | 1.424 | [0.6593-3.102] | 0.374 |
CCR6+ tumor cells | 1.929 | [0.986-3.772] | 0.055 |
CCL19+ DC | 2.277 | [1.141-3.772] |
0.020
|
Overall Survival
| |||
Variable
|
Hazard Ratio
|
95% CI
|
p value
|
Tumor size (mm) | 1.027 | [1.006-1.049] |
0.012
|
Number of positive node | 1.118 | [1.066-1.173] |
< 0.001
|
SBR grade 2 (ref. SBR1) | 1.534 | [0.549-4.287] | 0.415 |
SBR grade 3 (ref. SBR1) | 1.931 | [0.666-5.605] | 0.226 |
Progesterone receptor (negative) | 1.419 | [0.751-2.678] | 0.281 |
CCR6+ tumor cells | 1.205 | [0.638-2.277] | 0.565 |
CCL19+ DC | 1.717 | [0.916-3.219] | 0.092 |